| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $28,395,442 | 3 | 100 |
| DENNER ALEXANDER J | 10 percent owner | 0 | $0 | 3 | $28.4M | $-28.4M |
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Over the last 12 months, insiders at Innoviva, Inc. have bought $0 and sold $28.4M worth of Innoviva, Inc. stock.
On average, over the past 5 years, insiders at Innoviva, Inc. have bought $4.38M and sold $105.17M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 62,000 shares for transaction amount of $814,196 was made by DENNER ALEXANDER J (10 percent owner) on 2023‑06‑15.
| 2025-03-06 | Sale | DENNER ALEXANDER J | 10 percent owner | 1.2M 1.9005% | $17.52 | $20.96M | +6.14% | |
| 2025-03-05 | Sale | DENNER ALEXANDER J | 10 percent owner | 270,374 0.4315% | $17.63 | $4.77M | +5.91% | |
| 2025-03-04 | Sale | DENNER ALEXANDER J | 10 percent owner | 151,175 0.2411% | $17.63 | $2.67M | +6.09% | |
| 2023-11-15 | Sale | Zhen Marianne | Chief Accounting Officer | 10,994 0.0173% | $13.99 | $153,810 | +16.83% | |
| 2023-06-15 | DENNER ALEXANDER J | 10 percent owner | 62,000 0.0912% | $13.13 | $814,196 | +11.09% | ||
| 2023-06-06 | DENNER ALEXANDER J | 10 percent owner | 8,000 0.0118% | $13.05 | $104,384 | +10.41% | ||
| 2023-06-05 | DENNER ALEXANDER J | 10 percent owner | 7,000 0.0102% | $13.04 | $91,297 | +9.05% | ||
| 2023-05-30 | DENNER ALEXANDER J | 10 percent owner | 120,000 0.1775% | $13.01 | $1.56M | +7.09% | ||
| 2023-05-26 | DENNER ALEXANDER J | 10 percent owner | 30,000 0.0442% | $13.12 | $393,729 | +5.48% | ||
| 2023-05-25 | DENNER ALEXANDER J | 10 percent owner | 50,000 0.0735% | $13.09 | $654,330 | +5.48% | ||
| 2023-05-19 | DENNER ALEXANDER J | 10 percent owner | 36,000 0.0531% | $13.48 | $485,147 | +1.63% | ||
| 2023-05-18 | DENNER ALEXANDER J | 10 percent owner | 10,000 0.0146% | $13.05 | $130,538 | +3.71% | ||
| 2023-05-17 | DENNER ALEXANDER J | 10 percent owner | 50,000 0.0736% | $13.07 | $653,690 | +4.39% | ||
| 2023-05-11 | DENNER ALEXANDER J | 10 percent owner | 290,000 0.4246% | $12.34 | $3.58M | +9.81% | ||
| 2023-03-10 | Raifeld Pavel | Chief Executive Officer | 3,000 0.0045% | $10.87 | $32,603 | +22.61% | ||
| 2021-08-20 | Sale | Zhen Marianne | Chief Accounting Officer | 1,129 0.0016% | $15.89 | $17,940 | +3.07% | |
| 2021-08-19 | Sale | Zhen Marianne | Chief Accounting Officer | 2,802 0.004% | $16.02 | $44,888 | +2.50% | |
| 2021-05-24 | Bickerstaff George | director | 10,000 0.0112% | $13.46 | $134,619 | +21.34% | ||
| 2021-05-21 | Bickerstaff George | director | 10,000 0.0111% | $12.97 | $129,670 | +24.75% | ||
| 2021-05-20 | Sale | GLAXOSMITHKLINE PLC | 10 percent owner | 32.01M 33.288% | $12.25 | $392.06M | +23.35% |
| DENNER ALEXANDER J | 10 percent owner | 5658705 9.0142% | $110.74M | 10 | 3 | +6.82% |
| Aguiar Michael W | President & Chief Exec Officer | 980907 1.5626% | $19.2M | 0 | 9 | |
| Winningham Rick E | Chief Executive Officer | 690106 1.0993% | $13.51M | 1 | 10 | +19.7% |
| Shafer Bradford J | Sr VP, Gen. Counsel, Secretary | 446274 0.7109% | $8.73M | 1 | 9 | <0.0001% |
| dEsparbes Eric | SVP and CFO | 373081 0.5943% | $7.3M | 0 | 9 | |
| ABERCROMBIE GEORGE B | Sr. VP & Chief Comm. Officer | 285479 0.4548% | $5.59M | 0 | 4 | |
| GLICK MARTY | Executive VP, Finance and CFO | 267805 0.4266% | $5.24M | 1 | 0 | <0.0001% |
| Witek Theodore J. Jr. | Sr. VP & Chief Scientific Off. | 247767 0.3947% | $4.85M | 0 | 5 | |
| Mammen Mathai | SVP, Research & Early Clin Dev | 211705 0.3372% | $4.14M | 0 | 7 | |
| BLUM LEONARD M | Sr VP, Chief Comm. Officer | 158618 0.2527% | $3.1M | 3 | 0 | +41.61% |
| Bickerstaff George | director | 124560 0.1984% | $2.44M | 4 | 0 | +6.52% |
| WALTRIP WILLIAM H | director | 123604 0.1969% | $2.42M | 0 | 1 | |
| VAGELOS P ROY | director | 71499 0.1139% | $1.4M | 2 | 0 | +22.34% |
| Tyree James L | director | 50697 0.0808% | $992,140.29 | 0 | 2 | |
| Brinkley David L | Head of Business Dev. | 48749 0.0777% | $954,017.93 | 0 | 20 | |
| Zhen Marianne | Chief Accounting Officer | 40158 0.064% | $785,892.06 | 0 | 5 | |
| YOUNG WILLIAM D | director | 34129 0.0544% | $667,904.53 | 0 | 3 | |
| DRAZAN JEFFREY M | director | 33465 0.0533% | $654,910.05 | 0 | 4 | |
| Kitt Michael | Sr. Vice President Development | 30738 0.049% | $601,542.66 | 0 | 5 | |
| Humphrey Patrick PA | Executive VP Research | 11000 0.0175% | $215,270.00 | 1 | 0 | <0.0001% |
| Raifeld Pavel | Chief Executive Officer | 9799 0.0156% | $191,766.43 | 1 | 0 | +22.61% |
| HULME GEOFFREY | Interim PEO | 7000 0.0112% | $136,990.00 | 1 | 0 | <0.0001% |
| Sturmer A Gregory | Vice President Finance | 290 0.0005% | $5,675.30 | 1 | 0 | <0.0001% |
| BAKER JULIAN | director | 0 0% | $0 | 0 | 1 | |
| GLAXOSMITHKLINE PLC | 10 percent owner | 0 0% | $0 | 9 | 1 | +1.07% |
| Loewenthal Ronn | director | 0 0% | $0 | 0 | 1 |
$8,217,280 | 112 | 46.33% | $1.13B | |
$831,902,292 | 108 | 9.34% | $1.14B | |
$1,101,324,300 | 58 | 37.37% | $1.06B | |
$42,463,802 | 57 | 17.85% | $1.38B | |
$100,002,191 | 42 | 21.48% | $1.24B | |
Innoviva, Inc. (INVA) | $530,111,731 | 35 | 8.69% | $1.23B |
$18,659,984 | 32 | -10.07% | $1.33B | |
$149,456,352 | 27 | -8.77% | $1.34B | |
$54,828,550 | 26 | -13.88% | $1.01B | |
$1,272,896 | 16 | 24.56% | $1.17B | |
$153,334,329 | 15 | -5.01% | $972.55M | |
$50,317,062 | 13 | -3.69% | $992.99M | |
$9,976,473 | 12 | 29.52% | $1.1B | |
$43,198,628 | 12 | -0.10% | $1.35B | |
$20,499,451 | 9 | 71.54% | $1.42B | |
$107,703,099 | 7 | 29.71% | $1.3B | |
$91,325,021 | 6 | 1.83% | $1.28B | |
$46,235,722 | 6 | -31.77% | $1.25B | |
$18,704,399 | 5 | -20.93% | $1.04B |
| Increased Positions | 124 | +46.97% | 8M | +11.25% |
| Decreased Positions | 114 | -43.18% | 11M | -15.4% |
| New Positions | 40 | New | 2M | New |
| Sold Out Positions | 27 | Sold Out | 754,189 | Sold Out |
| Total Postitions | 274 | +3.79% | 68M | -4.15% |
| Blackrock, Inc. | $172,499.00 | 14.63% | 9.21M | -309,567 | -3.25% | 2025-03-31 |
| Sarissa Capital Management Lp | $136,225.00 | 11.55% | 7.28M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $118,172.00 | 10.02% | 6.31M | +84,934 | +1.36% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $92,093.00 | 7.81% | 4.92M | +226,592 | +4.83% | 2024-12-31 |
| Franklin Resources Inc | $82,973.00 | 7.04% | 4.43M | -2M | -34.29% | 2024-12-31 |
| Renaissance Technologies Llc | $79,780.00 | 6.77% | 4.26M | -68,175 | -1.57% | 2024-12-31 |
| Pacer Advisors, Inc. | $54,889.00 | 4.65% | 2.93M | +121,162 | +4.31% | 2024-12-31 |
| State Street Corp | $46,026.00 | 3.9% | 2.46M | +8,036 | +0.33% | 2024-12-31 |
| Systematic Financial Management Lp | $37,984.00 | 3.22% | 2.03M | +49,996 | +2.53% | 2024-12-31 |
| Goldman Sachs Group Inc | $32,606.00 | 2.77% | 1.74M | +579,904 | +49.91% | 2024-12-31 |